452 related articles for article (PubMed ID: 35633470)
1. Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.
Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Romita P; Raimondo A; Loconsole F; Fabbrocini G
Clin Drug Investig; 2022 Jun; 42(6):525-531. PubMed ID: 35633470
[TBL] [Abstract][Full Text] [Related]
2. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature.
Snast I; Atzmony L; Braun M; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Jul; 77(1):88-97.e5. PubMed ID: 28495497
[TBL] [Abstract][Full Text] [Related]
3. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations.
Piaserico S; Messina F; Russo FP
Am J Clin Dermatol; 2019 Dec; 20(6):829-845. PubMed ID: 31222626
[TBL] [Abstract][Full Text] [Related]
4. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study.
Chiu HY; Hui RC; Huang YH; Huang RY; Chen KL; Tsai YC; Lai PJ; Wang TS; Tsai TF
Acta Derm Venereol; 2018 Oct; 98(9):829-834. PubMed ID: 29972221
[TBL] [Abstract][Full Text] [Related]
5. Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
Bonifati C; Lora V; Graceffa D; Nosotti L
World J Gastroenterol; 2016 Jul; 22(28):6444-55. PubMed ID: 27605880
[TBL] [Abstract][Full Text] [Related]
6. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection.
Liu S; He Z; Wu W; Jin H; Cui Y
Clin Rheumatol; 2023 Sep; 42(9):2369-2376. PubMed ID: 37219751
[TBL] [Abstract][Full Text] [Related]
7. Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study.
Chiu HY; Chiu YM; Chang Liao NF; Chi CC; Tsai TF; Hsieh CY; Hsieh TY; Lai KL; Chiu TM; Wu NL; Hui RC; Lee CN; Wang TS; Chen PH; Yang CC; Huang YH
J Am Acad Dermatol; 2021 Aug; 85(2):337-344. PubMed ID: 31821860
[TBL] [Abstract][Full Text] [Related]
8. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
Cho YT; Chen CH; Chiu HY; Tsai TF
J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
10. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of secukinumab in psoriasis patients infected with hepatitis B virus: a retrospective study.
Qin H; Liu N; Hu Y; Yu N; Yi X; Gao Y; Chen F; Gu J; Ding Y; Shi Y
Eur J Dermatol; 2022 May; 32(3):394-400. PubMed ID: 36065536
[TBL] [Abstract][Full Text] [Related]
12. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database.
Sanz-Bueno J; Vanaclocha F; García-Doval I; Torrado R; Carretero G; Daudén E; Patricia Ruiz-Genao D; Alsina-Gibert MM; Pérez-Zafrilla B; Pérez-Rial G; Rivera R;
Actas Dermosifiliogr; 2015; 106(6):477-82. PubMed ID: 25776200
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
[TBL] [Abstract][Full Text] [Related]
14. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C.
Chiu HY; Chen CH; Wu MS; Cheng YP; Tsai TF
Br J Dermatol; 2013 Dec; 169(6):1295-303. PubMed ID: 23746170
[TBL] [Abstract][Full Text] [Related]
15. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab.
Ting SW; Chen YC; Huang YH
Clin Drug Investig; 2018 Sep; 38(9):873-880. PubMed ID: 29968197
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV).
Pisaturo M; Macera M; Alessio L; Calò F; Coppola N
Viruses; 2019 Sep; 11(9):. PubMed ID: 31540223
[TBL] [Abstract][Full Text] [Related]
17. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis.
Morisco F; Guarino M; La Bella S; Di Costanzo L; Caporaso N; Ayala F; Balato N
BMC Gastroenterol; 2014 Dec; 14():214. PubMed ID: 25523080
[TBL] [Abstract][Full Text] [Related]
18. The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy.
Stroffolini T; Sagnelli E; Sagnelli C; Smedile A; Furlan C; Morisco F; Coppola N; Andriulli A; Almasio PL
Dig Liver Dis; 2019 Mar; 51(3):434-437. PubMed ID: 30361062
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
Lee YH; Bae SC; Song GG
Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
[TBL] [Abstract][Full Text] [Related]
20. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma.
Guarino M; Picardi M; Vitello A; Pugliese N; Rea M; Cossiga V; Pane F; Caporaso N; Morisco F
Ann Hepatol; 2017; 16(2):198-206. PubMed ID: 28233742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
